Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?

Multiple Sclerosis and Related Disorders(2020)10.1016/j.msard.2020.102120Source: DataRank Database

COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? is a research paper published in Multiple Sclerosis and Related Disorders (2020). On theSindex it has a DataRank of 0. It has been cited 166 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access166 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Topics (14)Linked Datasets (18)DataCite Reuse (18)IDs (PubMed, PMC)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Małgorzata Mikulska ORCID,Federica Briano ORCID,Federica Toscanini,Francesco Tazza ORCID,Antonio Uccelli ORCID

Live enrichment

PubMed:32315980 PMC:PMC7156942

Genzyme

Biogen

Roche

Novartis

Fondazione Italiana Sclerosi Multipla

National Institutes of Health

MeSH Terms

HumansPneumonia, ViralCoronavirus InfectionsMultiple Sclerosis, Chronic ProgressiveImmunologic FactorsSeverity of Illness IndexMiddle AgedMalePandemicsAntibodies, Monoclonal, HumanizedProtective FactorsBetacoronavirusCOVID-19SARS-CoV-2

Additional file 1 of Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

10.6084/m9.figshare.14344442.v1figshare

Additional file 1 of Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

10.6084/m9.figshare.14344442figshare

Additional file 2 of Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

10.6084/m9.figshare.14344445.v1figshare

Additional file 2 of Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

10.6084/m9.figshare.14344445figshare

Additional file 3 of Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

10.6084/m9.figshare.14344448.v1figshare

Additional file 3 of Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

10.6084/m9.figshare.14344448figshare

Additional file 4 of Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

10.6084/m9.figshare.14344451.v1figshare

Additional file 4 of Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

10.6084/m9.figshare.14344451figshare

Additional file 5 of Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

10.6084/m9.figshare.14344454.v1figshare

Additional file 5 of Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

10.6084/m9.figshare.14344454figshare

Additional file 6 of Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

10.6084/m9.figshare.14344457.v1figshare

Additional file 6 of Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

10.6084/m9.figshare.14344457figshare

Additional file 7 of Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

10.6084/m9.figshare.14344460.v1figshare

Additional file 7 of Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

10.6084/m9.figshare.14344460figshare

Additional file 8 of Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

10.6084/m9.figshare.14344463.v1figshare

Additional file 8 of Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

10.6084/m9.figshare.14344463figshare

Additional file 9 of Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

10.6084/m9.figshare.14344466.v1figshare

Additional file 9 of Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

10.6084/m9.figshare.14344466figshare

Related Papers (10)

Ocrelizumab: A Review in Multiple Sclerosis

Drugs(2022)

OpenAlex related

10.1007/s40265-022-01672-9

Moving forward through the in silico modeling of multiple sclerosis: Treatment layer implementation and validation

Computational and Structural Biotechnology Journal(2023)

OpenAlex related

10.1016/j.csbj.2023.05.020

NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab

Multiple Sclerosis and Related Disorders(2024)

OpenAlex related

10.1016/j.msard.2024.105594

Ocrelizumab zur Behandlung der Multiplen Sklerose

Der Nervenarzt(2020)

OpenAlex related

10.1007/s00115-020-00937-6

Beyond ocrelizumab in primary progressive multiple sclerosis

Nature Reviews Neurology(2022)

OpenAlex related

10.1038/s41582-022-00724-8

Ocrelizumab and Cladribine Had Similar EDSS Stability in Patients with Highly Active Multiple Sclerosis

Multiple Sclerosis and Related Disorders(2023)

OpenAlex related

10.1016/j.msard.2023.105330

Additional possible mechanisms of the action of ocrelizumab in multiple sclerosis on example of a case-report

S S Korsakov Journal of Neurology and Psychiatry(2018)

OpenAlex related

10.17116/jnevro2018118082116

Ocrelizumab for multiple sclerosis

Cochrane Database of Systematic Reviews(2019)

OpenAlex related

10.1002/14651858.cd013247

Recent advance in disease-modifying drugs for multiple sclerosis

Chinese Journal of Neuromedicine(2019)

OpenAlex related

10.3760/cma.j.issn.1671-8925.2019.12.016

Ocrelizumab as a breakthrogh in multiple sclerosis treatment

Journal of Education Health and Sport(2021)

OpenAlex related

10.12775/jehs.2021.11.05.005